An in Vitro Assay of hERG K(+) Channel Potency for a New EGFR Inhibitor FHND004

FHND004 is a newly synthesized epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC). The aim of the present study was to investigate the impacts of FHND004 on human ether-à-go-go-related gene (hERG) K(+) channels and the molecular mechanisms under...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Tao, Hu, Bingxue, Chen, Shanshan, Wang, Qiang, Dong, Xue, Zhang, Yin, Zhu, Yongqiang, Zhang, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990611/
https://www.ncbi.nlm.nih.gov/pubmed/29904349
http://dx.doi.org/10.3389/fphar.2018.00577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990611/
https://www.ncbi.nlm.nih.gov/pubmed/29904349
http://dx.doi.org/10.3389/fphar.2018.00577

Ejemplares similares